TGFB1 and neoplasm: Nanodrugs targeting the tumor immune microenvironment enhance cancer immunotherapy by inhibiting immune suppressive cells (such as M2-like tumor-associated macrophages) and reducing the expression of immune suppressive molecules (such as transforming growth factor β) (Binnemars-Postma et al., 2017; Baig et al., 2020) Moreover, myeloid cells, like M2-like tumor-associated macrophages, are essential components of the tumor immune microenvironment playing an immunosuppressive role, often expressing factors that inhibit immune responses, such as transforming growth factor β (TGF-β).